GNR-060
Phase 3Biologic
GNR-060 is one of 36 biologic programs targeting ST Elevation Myocardial Infarction. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in ST Elevation Myocardial Infarction
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Farxiga
AstraZenecaApproved
Bayer Aspirin
BayerApproved
Adenocard
AstellasApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Kengreal
Chiesi Farmaceutici S.p.A.Approved
Jardiance
Boehringer IngelheimApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Inomax
MMallinckrodt
Approved
Unfractionated Heparin
GSKApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GNR-060. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAO GENERIUM